STAT+: FDA is ‘not convinced’ UniQure’s Huntington’s therapy has benefit, senior official says
RegulatorynegativeNegative
AI Analysis
Summary
The FDA has expressed skepticism regarding UniQure's experimental Huntington's disease therapy, stating it is not convinced the treatment provides patient benefit. This regulatory setback could significantly impact the company's development program for the indication.
Outcome Details
FDA is not convinced the experimental therapy provides benefit to patients
Importance:8/10
Sentiment:
-0.85
FDAHuntington's diseaseregulatory setbackrare disease
Related Companies
Read the original article
Published by STAT News on March 3, 2026 12:11 PM